Stereoselective (+)-6-Hydroxy-Morphinan for Microglial Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroinflammatory diseases and opiate dependence lack effective, stereoselective inhibitors of microglial activation, with existing mu opiate receptor antagonists exhibiting non-stereoselective inhibition and limited efficacy.
Innovation Solution
Development of substituted (+)-6-hydroxy- and (+)-6-amino-morphinan compounds that preferentially bind to microglia in the central nervous system, inhibiting their activation through specific synthesis processes involving condensation and reduction reactions with secondary amines and sodium cyanoborohydride.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mu opiate receptor antagonists ((-)-naloxone and (-)-naltrexone) are used to inhibit microglial activation, then microglial activation is inhibited, but the inhibition is non-stereoselective and efficacy is limited
Solution Approach 1:
The patent applies asymmetry by developing (+)-enantiomer morphinan compounds with specific chiral configurations that preferentially bind to microglia. The asymmetric synthesis produces enantiomerically pure compounds where the spatial arrangement of atoms creates stereoselective interactions with microglial receptors, thereby achieving stereoselective inhibition of microglial activation that was not achieved with the non-stereoselective (-)-naloxone and (-)-naltrexone
Solution Approach 2:
The patent applies local quality by introducing specific substitutions at position 6 of the morphinan ring (hydroxy or amino groups). These localized chemical modifications at a specific position on the molecule create enhanced local interactions with microglial targets, providing both stereoselectivity and improved microglial inhibitory activity compared to unfunctionalized precursors
2Reliability
If substitution at position 6 of the morphinan ring is introduced to create prodrugs, then activity is increased, but synthesis complexity increases
Solution Approach 1:
The patent applies preliminary action by performing asymmetric synthesis that directly produces the desired (+)-6-substituted morphinan enantiomers with correct stereochemistry from the outset. The synthesis methodology establishes the chiral centers and 6-position substitutions in a planned sequence, avoiding the need for later stereochemical corrections or complex separation procedures, thereby managing synthesis complexity while achieving enhanced activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized compounds demonstrate enhanced microglial inhibitory activity, providing a stereoselective approach to treating neuroinflammatory diseases and reducing opiate abuse and dependence by effectively inhibiting microglial activation.
Implementation Method 1
condensing a 6-keto morphinan with a secondary amine to form an enamine intermediate
Implementation Method 2
the enamine intermediate, which is then reduced to form a substituted 6-beta-amino morphinan
Data Source
AI summary
The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention.